EP1117406A1 - Antibiotic compositions for treatment of the eye, ear and nose - Google Patents

Antibiotic compositions for treatment of the eye, ear and nose

Info

Publication number
EP1117406A1
EP1117406A1 EP99950008A EP99950008A EP1117406A1 EP 1117406 A1 EP1117406 A1 EP 1117406A1 EP 99950008 A EP99950008 A EP 99950008A EP 99950008 A EP99950008 A EP 99950008A EP 1117406 A1 EP1117406 A1 EP 1117406A1
Authority
EP
European Patent Office
Prior art keywords
group
otic
ophthalmic
alkyl
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99950008A
Other languages
German (de)
French (fr)
Inventor
Gerald Cagle
Robert L. Abshire
David W. Stroman
John M. Yanni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of EP1117406A1 publication Critical patent/EP1117406A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the present invention is directed to the provision of topical antibiotic pharmaceutical compositions for the treatment of ophthalmic, otic and nasal infections, particularly bacterial infections, and to methods of treating ophthalmic, otic and nasal infections by applying those compositions to the affected tissues.
  • the compositions and methods of the invention are based on the use of a new class of antibiotics.
  • the compositions of the present invention may also contain one or more anti-inflammatory agents.
  • quinolone antibiotics to treat infections represents the current state of the art in the field of ophthalmic pharmaceutical compositions and methods of treatment.
  • a topical ophthalmic composition containing the quinolone ciprofloxacin is marketed by Alcon Laboratories, Inc. under the name CILOXANTM (Ciprofloxacin 0.3%) Ophthalmic Solution.
  • CILOXANTM Ciprofloxacin 0.3%) Ophthalmic Solution.
  • the following quinolones have also been utilized in ophthalmic antibiotic compositions:
  • Lomefloxacin LOMEFLOXTM Senju The foregoing quinolone antibiotic compositions are generally effective in treating ophthalmic infections, and have distinct advantages over prior ophthalmic antibiotic compositions, particularly those having relatively limited spectrums of antimicrobial activity, such as: neomycin, polymyxin B, gentamicin and tobramycin, which are primarily useful against gram negative pathogens; and bacitracin, gramicidin, and erythromycin, which are primarily active against gram positive pathogens.
  • Ophthalmic, otic and nasal infections are frequently accompanied by inflammation of the infected ophthalmic, otic and nasal tissues and perhaps even surrounding tissues.
  • ophthalmic, otic and nasal surgical procedures that create a risk of microbial infections frequently also cause inflammation of the affected tissues.
  • ophthalmic, otic and nasal pharmaceutical compositions that combine the anti- infective activity of one or more antibiotics with the anti-inflammatory activity of one or more steroid or non-steroid agents in a single composition.
  • the invention is based on the use of a potent new class of antibiotics to treat ophthalmic, otic and nasal infections, as well as the prophylactic use of these antibiotics following surgery or other trauma to ophthalmic, otic or nasal tissues.
  • the compositions of the present invention may also be administered to the affected tissues during ophthalmic, otic or nasal surgery procedures to prevent or alleviate post-surgical infections.
  • compositions preferably also contain one or more anti-inflammatory agents to treat inflammation associated with infections of ophthalmic, otic or nasal tissues.
  • the anti-inflammatory component of the compositions is also useful in treating inflammation associated with physical trauma to ophthalmic, otic or nasal tissues, including inflammation resulting from surgical procedures.
  • the compositions of the present invention are therefore particularly useful in treating inflammation associated with trauma to ophthalmic, otic or nasal tissues wherein there is either an infection or a risk of an infection resulting from the trauma.
  • compositions of the present invention examples include conjunctivitis, keratitis, blepharitis, dacyrocystitis, hordeolum and corneal ulcers.
  • the compositions of the invention may also be used prophylactically in connection with various ophthalmic surgical procedures that create a risk of infection.
  • otic conditions examples include otitis externa and otitis media.
  • the compositions of the present invention are primarily useful in cases where the tympanic membrane has ruptured or tympanostomy tubes have been implanted.
  • the compositions may also be used to treat infections associated with otic surgical procedures, such as tympanostomy, or to prevent such infections.
  • compositions of the present invention are specially formulated for topical application to ophthalmic, otic and nasal tissues.
  • the compositions are preferably sterile, and have physical properties (e.g., osmolality and pH) that are specially suited for application to ophthalmic, otic and nasal tissues, including tissues that have been compromised
  • the antibiotics used in the compositions and methods of the present invention have the following formula:
  • Rl is a cyclopropyl which may be substituted by 1 to 3 of substituents selected from the group consisting of a C C 6 alkyl and a halogen atom, a phenyl which may be substituted by 1 to 3 of substituents selected from the group consisting of C r C 6 alkoxy, a halogen atom and hydroxy, a C C 6 alkyl which may be substituted by a halogen atom, a C 2 -C 6 alkanoyloxy or hydroxy, a C 2 -C 6 alkenyl or thienyl;
  • R2 is a member selected from the group consisting of a 1 -piperazinyl group which may have 1 to 3 substituents selected from the group consisting of a C,-C 6 alkyl group, a C r C 6 alkanoyl group, a phenyl (C C 6 ) alkyl group, and a 2-oxo-l,3- dioxolenemethyl group which may be substituted by a phenyl group or a C r C 6 alkyl group; a 1 -pyrrolidinyl group which may have 1 to 3 substituents selected from the group consisting of an amino group which can have 1 or 2 substituents selected from a C r C 6 alkyl group and a (C r C 6 )alkooxy-carbonyl group, an amino(C C 6 )alkyl group which may have 1 to 2 substituents selected from C r C 6 alkyl group and a (C C 6 )alkoxy-carbonyl group on the amino
  • R3 is a C,-C 6 alkyl
  • R is hydrogen atom or a C C 6 alkyl
  • X is a halogen atom, or a pharmaceutically acceptable salt thereof.
  • Grepafloxacin has the following structure:
  • the concentrations of the antibiotics of formula (I) in the compositions of the present invention will vary depending on the intended use of the compositions (e.g., treatment of existing infections or prevention of post-surgical infections), and the relative antimicrobial activity of the specific antibiotic selected.
  • the antimicrobial activity of antibiotics is generally expressed as the minimum concentration required to inhibit the growth of a specified pathogen. This concentration is also referred to as the "minimum inhibitory concentration" or "MIC”.
  • MIC90 refers to the minimum concentration of antibiotic required to inhibit the growth of ninety percent (90%) of the strains of a species.
  • the concentration of an antibiotic required to totally kill a specified bacteria is referred to as the "minimum bactericidal concentration" or "MBC”.
  • MBC minimum bactericidal concentration
  • the minimum inhibitory concentration of Grepafloxacin for several bacteria commonly associated with ophthalmic, otic and nasal infections are provided in the following table:
  • the appropriate antibiotic concentration for ophthalmic compositions will generally be an amount of one or more antibiotics of formula (I) sufficient to provide a concentration in the aqueous humor and lacrimal fluid of the eye equal to or greater than the MIC90 level for the selected antibiotic(s), relative to gram-negative and gram-positive organisms commonly associated with ophthalmic infections.
  • the appropriate concentration for otic and nasal compositions will generally be an amount of one or more antibiotics of formula (I) sufficient to provide a concentration in the infected tissues equal to or greater than the MIC90 level for the selected antibiotic(s), relative to gram-negative and gram-positive organisms commonly associated with otic or nasal infections. Such amounts are referred to herein as "an antimicrobial effective amount”.
  • the compositions of the present invention will typically contain one or more compounds of formula (I) in a concentration of from about 0.1 to about 1.0 percent by weight (“wt. %”) of the compositions.
  • compositions of the present invention may also contain one or more anti- inflammatory agents.
  • the anti-inflammatory agents utilized in the present invention are broadly classified as steroidal or non-steroidal.
  • the preferred steroidal anti-inflammatory agents are glucocorticoids.
  • the preferred glucocorticoids for ophthalmic and otic use include dexamethasone, loteprednol, rimexolone, prednisolone, fluorometholone, and hydrocortisone.
  • the preferred glucocorticoids for nasal use include mometasone. fluticasone, beclomethasone. flunisolide, triamcinolone and budesonide.
  • dexamethasone derivatives described in U.S. Patent No. 5,223,493 are also preferred steroidal anti-inflammatory agents, particularly with respect to compositions for treating ophthalmic inflammation.
  • the following compounds are especially preferred:
  • 21 -ether derivatives of dexamethasone are referred to herein as "21 -ether derivatives of dexamethasone".
  • the 21-benzyl ether derivative i.e.. compound AL-2512
  • AL-2512 is particularly preferred.
  • the preferred non-steroidal anti-inflammatory agents are: prostaglandin H synthetase inhibitors (Cox I or Cox II), also referred to as cyclooxygenase type I and type II inhibitors, such as diclofenac, flurbiprofen, ketorolac, suprofen. nepafenac. amfenac.
  • indomethacin naproxen, ibuprofen, bromfenac, ketoprofen, meclofenamate, piroxicam, sulindac, mefanamic acid, diflusinal, oxaprozin, tolmetin, fenoprofen, benoxaprofen, nabumetome, etodolac, phenylbutazone. aspirin, oxyphenbutazone, NCX-4016.
  • HCT-1026 NCX-284, NCX-456, tenoxicam and carprofen
  • cyclooxygenase type II selective inhibitors such as NS-398, vioxx, celecoxib, P54, etodolac, L-804600 and S- 33516
  • PAF antagonists such as SR-27417, A-137491, ABT-299, apafant, bepafant, minopafant, E-6123, BN-50727, nupafant and modipafant
  • PDE IN inhibitors such as ariflo, torbafylline, rolipram, filaminast, piclamilast, cipamfylline, CG-1088, N-11294A, CT-2820, PD-168787, CP-293121, DWP-205297, CP-220629, SH-636, BAY-19-8004, and roflumilast
  • inhibitors of cytokine production
  • compositions of the present invention will vary based on the agent or agents selected and the type of inflammation being treated. The concentrations will be sufficient to reduce inflammation in the targeted ophthalmic, otic or nasal tissues following topical application of the compositions to those tissues. Such an amount is referred to herein as "an anti- inflammatory effective amount”.
  • the compositions of the present invention will typically containe one or more anti-inflammatory agents in an amount of from about 0.01 to about 1.0 wt.%.
  • compositions are typically administered to the affected ophthalmic, otic or nasal tissues by topically applying one to four drops of a sterile solution or suspension, or a comparable amount of an ointment, gel or other solid or semisolid composition, one to four times per day.
  • the compositions may also be formulated as irrigating solutions that are applied to the affected ophthalmic, otic or nasal tissues during surgical procedures.
  • the ophthalmic, otic and nasal compositions of the present invention will contain one or more compounds of formula (I) and preferably one or more anti-inflammatory agents, in pharmaceutically acceptable vehicles.
  • the compositions will typically have a pH in the range of 4.5 to 8.0.
  • the ophthalmic compositions must also be formulated to have osmotic values that are compatible with the aqueous humor of the eye and ophthalmic tissues. Such osmotic values will generally be in the range of from about 200 to about 400 milliosmoles per kilogram of water (“mOsm/kg”), but will preferably be about 300 mOsm/kg.
  • Ophthalmic, otic and nasal products are typically packaged in multidose form.
  • Preservatives are thus required to prevent microbial contamination during use.
  • Suitable preservatives include: polyquaternium- 1 , benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, or other agents known to those skilled in the art.
  • polyquaternium- 1 as the antimicrobial preservative is preferred.
  • such preservatives are employed at a level of from 0.001% to 1.0% by weight.
  • the solubility of the components of the present compositions may be enhanced by a surfactant or other appropriate co-solvent in the composition.
  • co-solvents include polysorbate 20, 60, and 80, polyoxyefhylene/poiyoxypropylene surfactants (e.g., Pluronic F-68, F-84 and P-103), cyclodextrin, or other agents known to those skilled in the art.
  • co-solvents are employed at a level of from 0.01% to 2% by weight.
  • viscosity enhancing agents to provide the compositions of the invention with viscosities greater than the viscosity of simple aqueous solutions may be desirable to increase absorption of the active compounds by the target tissues or increase the retention time in the eye, ear or nose.
  • viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose or other agents know to those skilled in the art. Such agents are typically employed at a level of from 0.01 % to 2% by weight.
  • Example 1 The following examples are provided to further illustrate the ophthalmic, otic and nasal compositions of the present invention.
  • Example 1

Abstract

Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.

Description

ANTIBIOTIC COMPOSITIONS FOR TREATMENT OF THE EYE, EAR AND NOSE
Background of the Invention
The present invention is directed to the provision of topical antibiotic pharmaceutical compositions for the treatment of ophthalmic, otic and nasal infections, particularly bacterial infections, and to methods of treating ophthalmic, otic and nasal infections by applying those compositions to the affected tissues. The compositions and methods of the invention are based on the use of a new class of antibiotics. The compositions of the present invention may also contain one or more anti-inflammatory agents.
The use of quinolone antibiotics to treat infections represents the current state of the art in the field of ophthalmic pharmaceutical compositions and methods of treatment. For example, a topical ophthalmic composition containing the quinolone ciprofloxacin is marketed by Alcon Laboratories, Inc. under the name CILOXAN™ (Ciprofloxacin 0.3%) Ophthalmic Solution. The following quinolones have also been utilized in ophthalmic antibiotic compositions:
Quinolone Product Manufacturer
Ofloxacin OCUFLOX™ Allergan
Norfloxacin CHIBROXiN™ Merck
Lomefloxacin LOMEFLOX™ Senju The foregoing quinolone antibiotic compositions are generally effective in treating ophthalmic infections, and have distinct advantages over prior ophthalmic antibiotic compositions, particularly those having relatively limited spectrums of antimicrobial activity, such as: neomycin, polymyxin B, gentamicin and tobramycin, which are primarily useful against gram negative pathogens; and bacitracin, gramicidin, and erythromycin, which are primarily active against gram positive pathogens. However, despite the general efficacy of the ophthalmic quinolone therapies currently available, there is a need for improved compositions and methods of treatment based on the use of antibiotics that are more effective than existing antibiotics against key ophthalmic pathogens, and less prone to the development of resistance by those pathogens.
There is an even greater need for effective topical compositions and methods for treating otic and nasal infections, particularly bacterial infections. The use of oral antibiotics to treat otic infections in children has limited efficacy, and creates a serious risk of pathogen resistance to the orally administered antibiotics.
Ophthalmic, otic and nasal infections are frequently accompanied by inflammation of the infected ophthalmic, otic and nasal tissues and perhaps even surrounding tissues. Similarly, ophthalmic, otic and nasal surgical procedures that create a risk of microbial infections frequently also cause inflammation of the affected tissues. Thus, there is also a need for ophthalmic, otic and nasal pharmaceutical compositions that combine the anti- infective activity of one or more antibiotics with the anti-inflammatory activity of one or more steroid or non-steroid agents in a single composition.
Summary of the Invention
The invention is based on the use of a potent new class of antibiotics to treat ophthalmic, otic and nasal infections, as well as the prophylactic use of these antibiotics following surgery or other trauma to ophthalmic, otic or nasal tissues. The compositions of the present invention may also be administered to the affected tissues during ophthalmic, otic or nasal surgery procedures to prevent or alleviate post-surgical infections.
The compositions preferably also contain one or more anti-inflammatory agents to treat inflammation associated with infections of ophthalmic, otic or nasal tissues. The anti-inflammatory component of the compositions is also useful in treating inflammation associated with physical trauma to ophthalmic, otic or nasal tissues, including inflammation resulting from surgical procedures. The compositions of the present invention are therefore particularly useful in treating inflammation associated with trauma to ophthalmic, otic or nasal tissues wherein there is either an infection or a risk of an infection resulting from the trauma.
Examples of ophthalmic conditions that may be treated with the compositions of the present invention include conjunctivitis, keratitis, blepharitis, dacyrocystitis, hordeolum and corneal ulcers. The compositions of the invention may also be used prophylactically in connection with various ophthalmic surgical procedures that create a risk of infection.
Examples of otic conditions that may be treated with the compostions of the present invention include otitis externa and otitis media. With respect to the treatment of otitis media, the compositions of the present invention are primarily useful in cases where the tympanic membrane has ruptured or tympanostomy tubes have been implanted. The compositions may also be used to treat infections associated with otic surgical procedures, such as tympanostomy, or to prevent such infections.
The compositions of the present invention are specially formulated for topical application to ophthalmic, otic and nasal tissues. The compositions are preferably sterile, and have physical properties (e.g., osmolality and pH) that are specially suited for application to ophthalmic, otic and nasal tissues, including tissues that have been compromised
Detailed Description of the Invention
The antibiotics used in the compositions and methods of the present invention have the following formula:
( I )
wherein
Rl is a cyclopropyl which may be substituted by 1 to 3 of substituents selected from the group consisting of a C C6 alkyl and a halogen atom, a phenyl which may be substituted by 1 to 3 of substituents selected from the group consisting of CrC6 alkoxy, a halogen atom and hydroxy, a C C6 alkyl which may be substituted by a halogen atom, a C2-C6 alkanoyloxy or hydroxy, a C2-C6 alkenyl or thienyl;
R2 is a member selected from the group consisting of a 1 -piperazinyl group which may have 1 to 3 substituents selected from the group consisting of a C,-C6 alkyl group, a CrC6 alkanoyl group, a phenyl (C C6) alkyl group, and a 2-oxo-l,3- dioxolenemethyl group which may be substituted by a phenyl group or a CrC6 alkyl group; a 1 -pyrrolidinyl group which may have 1 to 3 substituents selected from the group consisting of an amino group which can have 1 or 2 substituents selected from a CrC6 alkyl group and a (CrC6)alkooxy-carbonyl group, an amino(C C6)alkyl group which may have 1 to 2 substituents selected from CrC6 alkyl group and a (C C6)alkoxy-carbonyl group on the amino moiety, and a CrC6 alkyl group; a morpholino group which may have 1 to 3 substituents of CrC6 alkyl groups; a 1 -piperidinyl group which may have 1 to 3 substituents selected from the group consisting of a CrC6 alkyl group, hydroxy, a halogen atom and oxo group; and a l,4-diazobicyclo[4.3.0]nonan-4-yl group;
R3 is a C,-C6 alkyl;
R is hydrogen atom or a C C6 alkyl; and
X is a halogen atom, or a pharmaceutically acceptable salt thereof.
The compound Grepafloxacin is most preferred. Grepafloxacin has the following structure:
Further details regarding the structure, preparation, and physical properties of Grepafloxacin and other compounds of formula (I) are provided in U. S. Patent No. 5,563,138. The concentrations of the antibiotics of formula (I) in the compositions of the present invention will vary depending on the intended use of the compositions (e.g., treatment of existing infections or prevention of post-surgical infections), and the relative antimicrobial activity of the specific antibiotic selected. The antimicrobial activity of antibiotics is generally expressed as the minimum concentration required to inhibit the growth of a specified pathogen. This concentration is also referred to as the "minimum inhibitory concentration" or "MIC". The term "MIC90" refers to the minimum concentration of antibiotic required to inhibit the growth of ninety percent (90%) of the strains of a species. The concentration of an antibiotic required to totally kill a specified bacteria is referred to as the "minimum bactericidal concentration" or "MBC". The minimum inhibitory concentration of Grepafloxacin for several bacteria commonly associated with ophthalmic, otic and nasal infections are provided in the following table:
Microorganism MIC qn S. aureus/methicillin sensitive 0.13
S. aureus/methicillin resistant 0.13 S. aureus/quinolone resistant 0.13
S. epidermidis/methicillin sensitive 0.13
S. epidermidis/methicillin resistant 0.13 S. pneumoniae/penicillin sensitive 0.25
S. pneumoniae/penicillin resistant 0.25
P. aeruginosa 8.0
H. influenzae/β-lactamase positive 0.008
H influenzae/βlactamase negative 0.008
All of the foregoing concentrations are expressed as micrograms per milliliter ("mcg/ml").
The appropriate antibiotic concentration for ophthalmic compositions will generally be an amount of one or more antibiotics of formula (I) sufficient to provide a concentration in the aqueous humor and lacrimal fluid of the eye equal to or greater than the MIC90 level for the selected antibiotic(s), relative to gram-negative and gram-positive organisms commonly associated with ophthalmic infections. The appropriate concentration for otic and nasal compositions will generally be an amount of one or more antibiotics of formula (I) sufficient to provide a concentration in the infected tissues equal to or greater than the MIC90 level for the selected antibiotic(s), relative to gram-negative and gram-positive organisms commonly associated with otic or nasal infections. Such amounts are referred to herein as "an antimicrobial effective amount". The compositions of the present invention will typically contain one or more compounds of formula (I) in a concentration of from about 0.1 to about 1.0 percent by weight ("wt. %") of the compositions.
The compositions of the present invention may also contain one or more anti- inflammatory agents. The anti-inflammatory agents utilized in the present invention are broadly classified as steroidal or non-steroidal. The preferred steroidal anti-inflammatory agents are glucocorticoids.
The preferred glucocorticoids for ophthalmic and otic use include dexamethasone, loteprednol, rimexolone, prednisolone, fluorometholone, and hydrocortisone. The preferred glucocorticoids for nasal use include mometasone. fluticasone, beclomethasone. flunisolide, triamcinolone and budesonide.
The dexamethasone derivatives described in U.S. Patent No. 5,223,493 (Boltralik) are also preferred steroidal anti-inflammatory agents, particularly with respect to compositions for treating ophthalmic inflammation. The following compounds are especially preferred:
These compounds are referred to herein as "21 -ether derivatives of dexamethasone". The 21-benzyl ether derivative (i.e.. compound AL-2512) is particularly preferred.
The preferred non-steroidal anti-inflammatory agents are: prostaglandin H synthetase inhibitors (Cox I or Cox II), also referred to as cyclooxygenase type I and type II inhibitors, such as diclofenac, flurbiprofen, ketorolac, suprofen. nepafenac. amfenac. indomethacin, naproxen, ibuprofen, bromfenac, ketoprofen, meclofenamate, piroxicam, sulindac, mefanamic acid, diflusinal, oxaprozin, tolmetin, fenoprofen, benoxaprofen, nabumetome, etodolac, phenylbutazone. aspirin, oxyphenbutazone, NCX-4016. HCT-1026, NCX-284, NCX-456, tenoxicam and carprofen; cyclooxygenase type II selective inhibitors, such as NS-398, vioxx, celecoxib, P54, etodolac, L-804600 and S- 33516; PAF antagonists, such as SR-27417, A-137491, ABT-299, apafant, bepafant, minopafant, E-6123, BN-50727, nupafant and modipafant; PDE IN inhibitors, such as ariflo, torbafylline, rolipram, filaminast, piclamilast, cipamfylline, CG-1088, N-11294A, CT-2820, PD-168787, CP-293121, DWP-205297, CP-220629, SH-636, BAY-19-8004, and roflumilast; inhibitors of cytokine production, such as inhibitors of the ΝFkB transcription factor; or other anti-inflammatory agents known to those skilled in the art.
The concentrations of the anti-inflammatory agents contained in the compositions of the present invention will vary based on the agent or agents selected and the type of inflammation being treated. The concentrations will be sufficient to reduce inflammation in the targeted ophthalmic, otic or nasal tissues following topical application of the compositions to those tissues. Such an amount is referred to herein as "an anti- inflammatory effective amount". The compositions of the present invention will typically containe one or more anti-inflammatory agents in an amount of from about 0.01 to about 1.0 wt.%.
The compositions are typically administered to the affected ophthalmic, otic or nasal tissues by topically applying one to four drops of a sterile solution or suspension, or a comparable amount of an ointment, gel or other solid or semisolid composition, one to four times per day. However, the compositions may also be formulated as irrigating solutions that are applied to the affected ophthalmic, otic or nasal tissues during surgical procedures.
The ophthalmic, otic and nasal compositions of the present invention will contain one or more compounds of formula (I) and preferably one or more anti-inflammatory agents, in pharmaceutically acceptable vehicles. The compositions will typically have a pH in the range of 4.5 to 8.0. The ophthalmic compositions must also be formulated to have osmotic values that are compatible with the aqueous humor of the eye and ophthalmic tissues. Such osmotic values will generally be in the range of from about 200 to about 400 milliosmoles per kilogram of water ("mOsm/kg"), but will preferably be about 300 mOsm/kg.
Ophthalmic, otic and nasal products are typically packaged in multidose form.
Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: polyquaternium- 1 , benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, or other agents known to those skilled in the art. The use of polyquaternium- 1 as the antimicrobial preservative is preferred. Typically such preservatives are employed at a level of from 0.001% to 1.0% by weight.
The solubility of the components of the present compositions may be enhanced by a surfactant or other appropriate co-solvent in the composition. Such co-solvents include polysorbate 20, 60, and 80, polyoxyefhylene/poiyoxypropylene surfactants (e.g., Pluronic F-68, F-84 and P-103), cyclodextrin, or other agents known to those skilled in the art. Typically such co-solvents are employed at a level of from 0.01% to 2% by weight.
The use of viscosity enhancing agents to provide the compositions of the invention with viscosities greater than the viscosity of simple aqueous solutions may be desirable to increase absorption of the active compounds by the target tissues or increase the retention time in the eye, ear or nose. Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose or other agents know to those skilled in the art. Such agents are typically employed at a level of from 0.01 % to 2% by weight.
The following examples are provided to further illustrate the ophthalmic, otic and nasal compositions of the present invention. Example 1
Ophthalmic/Otic/Nasal Solution
Ingredient Amount (wt. %)
Grepafloxacin 0.35
Sodium Acetate 0.03
Acetic Acid 0.04
Mannitol 4.60
EDTA 0.05
Benzalkonium Chloride 0.006
Water q.s. 100
Example 2 Ophthalmic/Otic/Nasal Suspension
Ingredient Amount (wt. %)
Grepafloxacin 0.3
Dexamethasone, Micronized USP 0.10
Benzalkonium Chloride 0.01
Edetate Disodium, USP 0.01
Sodium Chloride, USP 0.3
Sodium Sulfate, USP 1.2
Tyloxapol, USP 0.05
Hydroxyethylcellulose 0.25
Sulfuric Acid and/or
Sodium Hydroxide, NF q.s. for pH adjust
Purified Water, USP q.s. to 100 Example 3 Ophthalmic Ointment
Ingredient Amount (wt.%)
Grepafloxacin 0.35
Mineral Oil, USP 2.0
White petrolatium, USP q.s 100
Example 4
Ophthalmic Ointment
Ingredient Amount (wt.%)
Grepafloxacin 0.3
Fluorometholone Acetate, USP 0.1
Chlorobutanol, Anhydrous, NF 0.5
Mineral Oil/USP 5
White Petrolatum, USP q.s. 100
The invention has been described herein by reference to certain preferred embodiments. However, as obvious variations thereon will become apparent to those skilled in the art, the invention is not to be considered as limited thereto.

Claims

What is claimed is:
1. A topical ophthalmic, otic or nasal pharmaceutical composition comprising an antimicrobial effective amount of one or more compounds of the formula:
(I)
wherein
Rl is a cyclopropyl which may be substituted by 1 to 3 of substituents selected from the group consisting of a C C6 alkyl and a halogen atom; a phenyl which may be substituted by 1 to 3 of substituents selected from the group consisting of CrC6 alkoxy, a halogen atom and hydroxy; a CrC6 alkyl which may be substituted by a halogen atom, a C2-C6 alkanoyloxy or hydroxy; a C2-C6 alkenyl; or thienyl;
R2 is a member selected from the group consisting of a 1-piperazinyl group which may have 1 to 3 substituents selected from the group consisting of a CrC6 alkyl group, a CrC6 alkanoyl group, a phenyl (CrC6) alkyl group, and a 2-oxo-l,3- dioxolenemethyl group which may be substituted by a phenyl group or a C,-C6 alkyl group; a 1 -pyrrolidinyl group which may have 1 to 3 substituents selected from the group consisting of an amino group which can have 1 or 2 substituents selected from a CrC6 alkyl group and a (C C6)alkooxy-carbonyl group, an amino(CrC6)alkyl group which may have 1 to 2 substituents selected from CrC6 alkyl group and a (C C6)alkoxy-carbonyl group on the amino moiety, and a CrC6 alkyl group; a morpholino group which may have 1 to 3 substituents C,-C6 alkyl groups; a 1-piperidinyl group which may have 1 to 3 substituents selected from the group consisting of a C C6 alkyl group, hydroxy, a halogen atom and oxo group; and a l,4-diazobicyclo[4.3.0]nonan-4-yl group;
R3 is a CrC6 alkyl;
R is hydrogen atom or a C]-C6 alkyl; and
X is a halogen atom, or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable vehicle therefor.
2. A topical composition according to Claim 1, wherein the composition further comprises an anti-inflammatory effective amount of a steroidal or non-steroidal anti- inflammatory agent.
3. A topical composition according to Claim 2, wherein the anti-inflammatory agent comprises a glucocorticoid.
4. A topical composition according to Claim 3, wherein the glucocorticoid is selected from the group consisting of dexamethasone, rimexolone, prednisolone, fluorometholone, hydrocortisone, mometasone, fluticasone, beclomethasone, flunisolide, triamcinolone and budesonide.
5. A topical composition according to Claim 2, wherein the anti-inflammatory agent comprises a non-steroidal agent selected from the group consisting of prostaglandin H synthetase inhibitors, PAF antagonists, and PDE IN inhibitors.
6. A topical composition according to Claim 1 , wherein the compound of formula (I) comprises grepafloxacin.
7. A topical composition according to Claim 6, wherein the composition further comprises an anti-inflammatory effective amount of a steroidal or non-steroidal anti- inflammatory agent.
8. A method of treating or preventing ophthalmic, otic or nasal infections, which comprises topically applying a therapeutically effective amount of the composition of Claim 1 to the affected ophthalmic, otic or nasal tissue.
9. A method of treating or preventing ophthalmic, otic or nasal infections and attendant inflammation, which comprises topically applying a therapeutically effective amount of the composition of Claim 2 to the affected ophthalmic, otic or nasal tissue.
10. A method of treating or preventing ophthalmic, otic or nasal infections and attendant inflammation, which comprises topically applying a therapeutically effective amount of the composition of Claim 7 to the affected ophthalmic, otic or nasal tissue.
EP99950008A 1998-09-30 1999-09-29 Antibiotic compositions for treatment of the eye, ear and nose Withdrawn EP1117406A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10251098P 1998-09-30 1998-09-30
US10251198P 1998-09-30 1998-09-30
US102510P 1998-09-30
US102511P 1998-09-30
PCT/US1999/022625 WO2000018404A1 (en) 1998-09-30 1999-09-29 Antibiotic compositions for treatment of the eye, ear and nose

Publications (1)

Publication Number Publication Date
EP1117406A1 true EP1117406A1 (en) 2001-07-25

Family

ID=26799456

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99950008A Withdrawn EP1117406A1 (en) 1998-09-30 1999-09-29 Antibiotic compositions for treatment of the eye, ear and nose

Country Status (7)

Country Link
EP (1) EP1117406A1 (en)
JP (1) JP2002525326A (en)
AU (1) AU6275999A (en)
BR (1) BR9914158A (en)
CA (1) CA2344050A1 (en)
HK (1) HK1038692A1 (en)
WO (1) WO2000018404A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
BR0014203A (en) 1999-09-24 2002-05-21 Alcon Inc Topical suspension formulations containing ciprofloxacin and dexamethasone
DE19962470A1 (en) 1999-12-22 2001-07-12 Schulz Hans Herrmann Use of chemotherapy drugs
AU2005202737B2 (en) * 1999-12-22 2009-01-22 Bayer Innovation Gmbh Use of chemotherapeutic agents
DE19962353A1 (en) 1999-12-23 2001-07-05 Henkel Ecolab Gmbh & Co Ohg Hepatitis A virucide
US6608078B2 (en) 2000-05-08 2003-08-19 Wockhardt Limited Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
US6462033B2 (en) 2000-07-26 2002-10-08 Alcon Universal Ltd. Process for manufacturing compositions containing ciprofloxacin and hydrocortisone
US7098219B2 (en) 2000-08-01 2006-08-29 Wockhart Limited Inhibitors of cellular efflux pumps of microbes
US6878713B2 (en) 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6964966B2 (en) * 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US20030139382A1 (en) 2001-09-21 2003-07-24 Alcon, Inc. Method of treating middle ear infections
JP2005511743A (en) * 2001-12-13 2005-04-28 ウォックハート・リミテッド A new generation of triple-targeted chiral broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, methods for their preparation, compositions, and pharmaceutical use
US6664267B1 (en) 2002-05-28 2003-12-16 Wockhardt Limited Crystalline fluoroquinolone arginine salt form
CA2508762A1 (en) * 2002-12-06 2004-06-24 Arriva Pharmaceuticals, Inc. Methods and compositions for treatment of otitis media
ATE366734T1 (en) 2003-09-04 2007-08-15 Wockhardt Ltd BENZOQUINOLICIN 2-CARBONIC ACID ARGININE SALT TETRAHYDRATE
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
US20140219949A1 (en) * 2011-06-22 2014-08-07 Jiangsu Deda Pharmaceuticals Co. Ltd Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551456A (en) * 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
JP2549285B2 (en) * 1987-02-02 1996-10-30 第一製薬株式会社 Nasal spray
US5563138A (en) * 1987-04-16 1996-10-08 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
WO1990001933A1 (en) * 1988-08-26 1990-03-08 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
DK0782448T3 (en) * 1995-06-06 2002-07-08 Bayer Ag Non-irritating, non-sensitizing, non-ototoxic antibacterial ear preparations
JPH10130148A (en) * 1996-09-04 1998-05-19 Senju Pharmaceut Co Ltd Composition for nebulizer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0018404A1 *

Also Published As

Publication number Publication date
JP2002525326A (en) 2002-08-13
CA2344050A1 (en) 2000-04-06
BR9914158A (en) 2001-06-26
WO2000018404A1 (en) 2000-04-06
AU6275999A (en) 2000-04-17
HK1038692A1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
US6716830B2 (en) Ophthalmic antibiotic compositions containing moxifloxacin
EP1117401B1 (en) Antibiotic compositions for treatment of the eye
US6395746B1 (en) Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
WO2000018404A1 (en) Antibiotic compositions for treatment of the eye, ear and nose
US20020142999A1 (en) Antibiotic compositions for treatment of the eye, ear and nose
AU2003248033B2 (en) Antibiotic Compositions for Treatment of the Eye, Ear and Nose
ZA200101752B (en) Methods of treating or preventing ophthalmi infections with moxifloxacin.
MXPA01003295A (en) Antibiotic compositions for treatment of the eye, ear and nose
MXPA01003293A (en) Antibiotic compositions for treatment of the eye, ear and nose
AU2007201610A1 (en) Antibiotic compositions for treatment of the eye, ear and nose
MXPA01003294A (en) Antibiotic compositions for treatment of the eye, ear and nose

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010327

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20021115

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1038692

Country of ref document: HK